RxDoctor Payments Data

Frieda Millhouse-Jones, MD

Internal Medicine · Atlanta, GANPI 1144272568

Payments from drug & device makers

$7,023in general payments, 2019–2025

Across 348 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$820
  • Lilly USA, LLC$816
  • Abbott$689
  • Sanofi-aventis U.S. LLC$607
  • Corcept Therapeutics$462
  • AbbVie$245
  • plus $3K from 49 others

What the payments were for

  • Food & beverage$7,023100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,023 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$80,420
Medicare patients
163
Services billed
2,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide181$204,221
OzempicSemaglutide136$159,555
JardianceEmpagliflozin68$65,943
FarxigaDapagliflozin Propanediol69$46,381
EliquisApixaban37$37,130
TrulicityDulaglutide23$31,488
Synjardy XrEmpagliflozin/Metformin Hcl35$28,764
RybelsusSemaglutide13$23,495
Xigduo XrDapaglifloz Propaned/Metformin26$21,271
XareltoRivaroxaban20$20,816
Breo ElliptaFluticasone/Vilanterol37$16,920
SynthroidLevothyroxine Sodium41$4,182
Fluticasone-VilanterolFluticasone/Vilanterol12$3,936
Rosuvastatin Calcium353$3,454
Atorvastatin Calcium403$3,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$816$235,708204 claims
Novo NordiskOzempic, Rybelsus$820$183,050149 claims
Boehringer IngelheimJardiance, Synjardy Xr$213$94,707103 claims
AstraZenecaFarxiga$25$46,38169 claims
PfizerEliquis$124$37,13037 claims
Johnson & JohnsonXarelto$39$20,81620 claims
GSKBreo Ellipta$29$16,92037 claims
AbbVieSynthroid$245$4,18241 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$86$2,186163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →